Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 15/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065508 | 1.00 | ASGR1 (0.61) | ASGR1 | |
| SCHEMBL17274253 | 1.00 | ASGR1 (0.61) | ASGR1 | |
| SCHEMBL27232837 | 0.90 | ASGR1 (0.52) | ASGR1 | |
| SCHEMBL26878845 | 0.88 | ASGR1 (0.49) | ASGR1 | |
| SCHEMBL26900958 | 0.88 | ASGR1 (0.49) | ASGR1 | |
| SCHEMBL23706275 | 0.88 | ASGR1 (0.49) | ASGR1 | |
| SCHEMBL24256079 | 0.88 | ASGR1 (0.49) | ASGR1 | |
| SCHEMBL23346073 | 0.85 | ASGR1 (0.62) | ASGR1 | |
| SCHEMBL24724923 | 0.83 | ASGR1 (0.43) | ASGR1 | |
| SCHEMBL17268902 | 0.83 | ASGR1 (0.46) | ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-05 | — | — | US | disclosed |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-04 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11603532-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-14 | — | — | US | disclosed |
| US-11597927-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-07 | — | — | US | disclosed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
| US-20160207953-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207953-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-9340553-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340553-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340553-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| WO-2015177668-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-8999674-B2 | Methods and apparatus for single molecule sequencing using energy transfer detection | Life Technologies Corporation (US) | 2015-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, METTL3, RNASE1 | ASGR1 596/4885 |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ASGR1 569/4885 |
| US-20160207953-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885 |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | ASGR1 437/4885 |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885 |
| US-11597927-B2 | Oligonucleotide compositions and methods of use thereof | RNASE1, RNASEH1, NSUN3 | ASGR1 608/4885 |
| US-11603532-B2 | Oligonucleotide compositions and methods of use thereof | RNASE1, RNASEH1, RNASEL | ASGR1 385/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | ASGR1 2/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | ASGR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.